Scarica l'app Stockscreener
2.9122
2.93%
-0.0878
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.00
Aprire:
$3.03
Volume 24 ore:
87,399
Relative Volume:
0.06
Capitalizzazione di mercato:
$2.66M
Reddito:
-
Utile/perdita netta:
$-5.85M
Rapporto P/E:
-0.4355
EPS:
-6.6877
Flusso di cassa netto:
$-8.00M
1 W Prestazione:
-0.27%
1M Prestazione:
-23.96%
6M Prestazione:
-74.32%
1 anno Prestazione:
-91.70%
Intervallo 1D:
$2.90
$3.035
Intervallo di 1 settimana:
$2.8101
$3.05
Portata 52W:
$2.75
$135.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
Nome
Alzamend Neuro Inc
Settore
Industria
Telefono
844-722-6333
Indirizzo
3500 LENOX RD. NE, ATLANTA
Confronta ALZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.9122 | 2.66M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-01 | Iniziato | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
Alzamend Neuro (ALZN) Secures $5 Million in Private Placement | - GuruFocus
Fast-Tracked: $5M Investment Accelerates 5 Phase II Trials for Alzheimer's and Mental Health Breakthroughs - Stock Titan
Alzamend Neuro (NASDAQ:ALZN) Stock Rating Upgraded by Wall Street Zen - Defense World
Alzamend Neuro Stock: A Green Day Hiding Red Flags for Traders - thekhabrilal
Citadel Advisors LLC Makes New Investment in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Growth in Short Interest - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 18.6% in May - Defense World
Promising Pharmaceutical Stocks To Follow Today – May 29th - Defense World
Lithium Stocks To Consider – May 29th - Defense World
Alzamend Neuro begins phase II trial for novel lithium delivery system By Investing.com - Investing.com South Africa
Alzamend Neuro doses first patient in Phase II study of AL001 - TipRanks
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | - GuruFocus
Sector Update: Health Care - marketscreener.com
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Asianet Newsable
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled By Stocktwits - Investing.com India
Lithium Stocks To ConsiderMay 29th - MarketBeat
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone - Benzinga
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - Benzinga
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue - Benzinga
Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update - TipRanks
Alzamend Neuro Soars on Breakthrough Trial News: Is This Biotech Stock a Hidden Gem? - RagingBull
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Alzamend Neuro begins phase II trial for novel lithium delivery system - Investing.com Australia
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Dosing Of First Patient In Phase II Clinical Trial Of Al001 "Lithium In Brain" Study - marketscreener.com
Alzamend Neuro Announces Dosing of First Patient in its - GlobeNewswire
Novel Lithium Drug Enters Phase II Trial, Targets 43M Patients With Brain Disorders Without Blood Monitoring - Stock Titan
Alzamend Neuro (NASDAQ:ALZN) Trading Down 5.5% – Here’s What Happened - Defense World
Alzamend begins phase II trial for novel lithium therapy By Investing.com - Investing.com South Africa
Alzamend begins phase II trial for novel lithium therapy - Investing.com Australia
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Al - GuruFocus
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Alzheimer's Treatment | ALZN Stock News - GuruFocus
Alzamend Neuro Enrolls First Patient in its Phase II - GlobeNewswire
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study - marketscreener.com
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
Alzamend Neuro (ALZN) Begins Key Phase II Trials of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 'Lithium in Brain” Study Taking Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants - Benzinga
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
Alzamend Neuro to conduct reverse stock split - MSN
Alzamend Neuro adds partners for lithium study using specialty head coil - AuntMinnie
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com India
Alzamend Neuro Announces Reverse Stock Split Plan - TipRanks
Stock Market Recap: Alzamend Neuro Inc (ALZN) Concludes at 0.60, a -6.22 Surge/Decline - DWinneX
Alzamend Neuro (ALZN) Announces Reverse Stock Split | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Reverse Stock Split - The Manila Times
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements - Investing.com
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro partners with Mint Labs to support five upcoming trials - TipRanks
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered - GlobeNewswire
Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alzamend Neuro Inc Azioni (ALZN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
May 12 '25 |
Sale |
5.28 |
11 |
58 |
1,843 |
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):